February 27, 2024 – Canada-wide – JDRF Canada, an organization dedicated to improving the lives of the estimated 300,000 Canadians living with type 1 diabetes (T1D) through its advocacy efforts, is awaiting the imminent announcement of a new national pharmacare program that will include coverage of diabetes medications. Insulin was discovered in Canada by Banting, Collip and Best who then sold the patent to the University of Toronto for $1. Banting famously said, “Insulin does not belong to me, it belongs to the world.” He wanted everyone who needed it to have access to it. Making all insulins among the first treatments covered by pharmacare honours this historic legacy.
Another critical component that we look forward to seeing supported in the national pharmacare program is diabetes devices, such as advanced glucose monitors and insulin pumps.
Insulin pump therapy is a crucial tool for the management of diabetes in many people with the condition, particularly those with T1D. Compared with insulin therapy delivered with syringes or pens, insulin pump use is generally associated with improved glucose control, reduced hypoglycemia and other complications, and improved quality of life in people with T1D.
Furthermore, compared with conventional methods for blood glucose monitoring by finger-prick testing, advanced glucose monitors including Continuous Glucose Monitors (CGMs) and Flash Glucose Monitors (Flash GMs) have revolutionized diabetes management. These devices provide real-time glucose readings and trends, allowing individuals to make pro-active decisions about their diabetes management. They also provide clinicians with enhanced data to guide treatment decisions for their patients with diabetes. In people with T1D, these monitors not only improve the quality of life for people with diabetes but also glucose control, thereby reducing the risk of associated long-term complications.
A national pharmacare program that includes insulin and diabetes devices would show a deep commitment to ensuring equitable access to healthcare for all Canadians, regardless of their medical condition or socioeconomic status, as well as relieving an immense burden from our healthcare system.
For more information: Ruth Kapelus National Content and Media Relations Manager T. 647-789-2322 rkapelus@jdrf.ca
These awards support the career development of the next generation of health researchers. The REDI awards are available to post-doctoral researchers, clinicians, and research associates from specific underrepresented groups to help them launch their research faculty careers in Canada. The 2023 awards were open only to Black people and racialized women, which previous research identified as two groups that are markedly under-represented among academic faculty at Canadian universities.
This transition award is intended to foster the development of independent research scientists with tailored, mentored career development in Phase 1 (supervised research) before transitioning to Phase 2 (independent research position) and establishing and sustaining their independent research program in academia. The first competition was held in 2023, and JDRF partnered with CIHR to support two applicants in T1D.
Dr. Yi Chun Chen
Dr. Chen is a postdoctoral fellow at the University of British Columbia. Her research focuses on the causes and consequences of insufficient islet prohormone processing in diabetes. Her career goal is to establish an independent research program focused on studying the adaptive responses of beta cells during the development of T1D, to inform the design of therapeutics to protect beta cells in T1D. Dr. Chen previously held a JDRF-I postdoctoral fellowship award.
Dr. Hyekyoung (Cindy) Sung
Dr. Sung is a postdoctoral fellow at York University in Dr. Gary Sweeney’s laboratory. Her research studies the impact of adiponectin (a naturally occurring hormone primarily produced by fatty tissue) on regulation of glucose levels and insulin sensitivity. During this award she will characterize the importance of a certain immune pathway in T1D and carry out preclinical studies to test drugs that target this pathway as a possible way to prevent or treat T1D. Dr. Sung’s overarching career goal is to identify pathways important in T1D, characterize sub-types of disease, and work on new precision medicine approaches for T1D.
The CIHR REDI Awards help Canada nurture the full extent of its tremendous scientific talent by addressing gaps in training and fostering diversity. Supporting the next generation of researchers early in their careers helps build world-class T1D experts, facilitating innovative breakthroughs for years to come.
OPINION: Canada is on track to cure type 1 diabetes. With the right support, we can get there.
Research innovation is becoming increasingly competitive in the post-pandemic world and Canada is at risk of losing its foothold.
An estimated 300,000 Canadians (growing at a rate of 4.4% per year) live with type 1 diabetes (T1D), an autoimmune disease that occurs when the pancreas cannot produce enough insulin for the body, causing blood glucose to rise. Until cures are found, people with T1D must monitor their blood glucose throughout the day and take multiple daily insulin injections to survive. But insulin is only a treatment, and Canadians with T1D have a high risk of life-threatening complications, lower quality of life, and life expectancy that is 10 years less than the general population.
When it comes to diabetes research, Canada has historically punched well above its weight on the world stage. Since the discovery of insulin in Toronto in 1921, Canada has continued to make significant breakthroughs towards curing T1D; from the discovery of stem cells in 1961, to the development of the Edmonton Protocol – a method of transplanting pancreatic cells – in 1999.
In 2022, the federal government published the Framework for Diabetes in Canada; highlighting a need to better recognize, collaborate with, and support those impacted by diabetes. The Framework provides a common policy direction to help align national efforts to address diabetes. Like previous reports however, it recognizes that Canada continues to lack the necessary funding for diabetes research and for translating discoveries into practice. The federal government has an opportunity to make meaningful investments into research and demonstrate its leadership and commitment for better treatment and support for people living with diabetes.
Canada has the talent and capacity to continue its legacy of success and can be the place where the next major breakthroughs in T1D cures are discovered, driven to commercialization, and improve lives. But to maintain our leading research position and to reduce the immense pressure on our health care system caused by T1D and its complications, there needs to be sustained investment in research and innovation throughout the entire pipeline. That is why JDRF is recommending the federal government invest $50 million over 5 years in the JDRF-CIHR Partnership to Defeat Diabetes to fund new and existing translational T1D research – from discovery to clinical trials – to improve health outcomes, drive commercialization, create good jobs, and bolster Canada’s life sciences sector.
Funding translational research means bringing innovations to market. Investments in this space not only create jobs for research staff, highly qualified personnel, and students, but also allows for the potential of discoveries to spin-off into businesses. Without the right incentives, Canadian projects, and the research talent behind them, may choose to relocate to other countries with better opportunities. This leaves Canada in a position of starting research projects with heavy initial investment, but then losing out on the economic benefits that would flow from its discoveries, as well as the benefits of new treatments that Canadians need. By effectively moving research projects through the full pipeline into commercialization, Canada can demonstrate that it values innovation and that we can be a destination for attracting new talent and investments in this space.
Along with improving the lives of Canadians with T1D, bringing innovative solutions to market will also realize long-term benefits for governments looking to reduce health care costs (which in Canada are $27 billion due to diabetes). Innovations in T1D research reduce hospitalizations due to related complications (including diabetic ketoacidosis, hypoglycemia, kidney and cardiovascular disease, and mental health disorders), as well as improve quality of life and health outcomes, thereby reducing absenteeism and presenteeism related to T1D in working-age Canadians.
As research around the world brings us closer to cures for T1D, we cannot afford to abandon the progress we have made in Canada. It is crucial for our government to provide consistent and stable funding for Canadian researchers to launch the next moonshots that will transform T1D therapy – and lead to cures. Canada discovered insulin. Canada discovered stem cells and pioneered the Edmonton Protocol. Canada can lead the world in the discovery of a cure.
– Dr. Sarah Linklater, JDRF Canada Chief Scientific Officer
Toronto, Ontario, February 20, 2024 – JDRF Canada and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes (T1D), a chronic autoimmune condition, and the role screening could play in the early detection of this disease.
Nationally, the number of individuals diagnosed with T1D is growing at an estimated 4.4% per year. This places Canada among the countries in the world with the highest rate of new T1D cases each year. While many believe T1D is only diagnosed in childhood and adolescence, diagnosis in adulthood is common and accounts for over 50% of all T1D cases. Traditionally, a diagnosis of T1D follows the onset of clinical symptoms, such as excessive thirst, frequent urination, and weight loss, however, the underlying autoimmune damage on pancreatic beta cells begins long before these signs become apparent.
The evolution of T1D unfolds through three discernible stages, with the initial ‘silent’ phase characterized by the presence of autoantibodies and no overt symptoms. Creating awareness of the stages leading to the onset of clinical disease could mitigate the risk of diabetic ketoacidosis (DKA), a life-threatening condition that often accompanies the diagnosis of T1D. Early detection could help keep people out of the hospital and reduce significant financial burdens on the healthcare system.
Jessica Diniz,President and CEO, JDRF Canada
Through this partnership, JDRF Canada and Sanofi Canada will work to increase awareness of T1D and the potential of screening to benefit individuals and families at risk of the disease in the future. T1D screening is a key pillar of JDRF’s strategy internationally, as it has the power to detect who is at risk and, in turn, will enable the delivery of education and support to improve outcomes. This new partnership will focus on disseminating resources and support for Canadians at risk of developing T1D and their healthcare providers, to foster a culture of active health management.
Ahmed Moussa,General Manager, General Medicines, Sanofi Canada
At the core of our partnership with JDRF lies a shared commitment to shed light on the journey towards the onset of T1D. By illuminating the stages preceding clinical symptoms, we aim to equip individuals with the knowledge needed to make informed decisions about their health. Early detection can empower individuals to face an eventual diagnosis with the information and support to preemptively manage their condition.
About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. JDRF partners across the full T1D development pipeline – including academic institutions, governments and corporations – to fund research and advocate for the delivery of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit breakthrought1d.ca.
About Sanofi
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
In Canada, Sanofi employs over 2,000 people and invests annually of 20% of its revenue in biopharma research, representing CAD $1.2 billion in R&D over the last decade, creating jobs, business, and opportunities throughout the country. From our state-of-the-art Campus in Toronto, we research, develop, manufacture, commercialize and distribute Sanofi products to people in this country and around the world.
In 2024, we are celebrating 110 years of heritage. What started as a small laboratory in May of 1914, has evolved to become the largest biomanufacturing facility in Canada. Today, we remain committed to discovering, developing, and delivering innovative medicine and vaccine solutions for people that need them.
For media inquiries or further information, please contact:
Ruth Kapelus National Content & Media Relations Manager, JDRF Canada
JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, joins healthcare and humanitarian non-profits throughout the world in calling for a medical corridor to allow immediate access to lifesaving supplies and medicines, like insulin, needed by all people living with T1D in the Middle East conflict zone. At all times, including times of conflict, people with T1D need insulin to live, regardless of race, religion, or national origin. JDRF urges those with influence in the region to aid in preserving life by joining our organization in supporting this effort.
JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, has awarded $12 million to researchers Dr. Alessandro Doria with Joslin Diabetes Center, Dr. Michael Mauer with the University of Minnesota Medical School, and Dr. David Cherney at the University Health Network, University of Toronto, to conduct a pivotal clinical trial that will test sotagliflozin, a dual sodium-glucose cotransporter (SGLT)1 and SGLT2 inhibitor, in the treatment of kidney complications in people with T1D. The study will build on the SUGARNSALT research project first led by Dr. Cherney, which is supported by a $1 million commitment from The Kidney Foundation of Canada (KFOC) matched by a $1 million investment by the Canadian Institutes of Health Research (CIHR) through the Team Grant: Diabetes Mechanisms and Translational Solutions competition, launched in 2022.
Kidney disease remains a life-threatening complication for those living with diabetes. Almost half of kidney failure cases are caused by diabetes, and an estimated one out of three people with T1D develop significant kidney disease. In recent years, SGLT inhibitors have proven to be very effective in improving kidney outcomes in people with type 2 diabetes, but there remains a lack of research on their effectiveness for those with T1D and established diabetic kidney disease. With few approved therapies for people with T1D who have developed kidney disease and the substantial risk of kidney disease progression despite current treatments available for such patients, this study is an important step toward fulfilling an unmet clinical need and allowing these individuals to live longer and healthier lives.
The trial will be conducted at sites across the U.S. and Canada, and enrollment is expected to begin in May 2024.
JDRF Canada is thrilled to continue a successful partnership with the Canadian Islet Research and Training Network (CIRTN) and announce a second cohort of co-funded trainees beginning in 2024.
CIRTN was established in 2020 as a world-class training and research network with joint contributions from the University of Alberta, University of British Columbia, University of Manitoba, Université de Montréal, Institut de Recherches Cliniques de Montréal, and the University of Toronto and now includes 12 institutions from across Canada. JDRF Canada has partnered with CIRTN to leverage funding to this network from the National Science and Engineering Research Council – Collaborative Research and Training Experience (NSERC-CREATE) program. See 2023 cohort trainees here.
Nerea Cuesta-Gomez, PhD
Postdoctoral Fellow
Supervisor: Greg Korbutt, University of Alberta
Improved b-cell engraftment and survival through graft localized therapeutic delivery systems.
Islet transplantation can reverse diabetes, however, approximately 60% of the cells die shortly after transplant. Limited donor supply in combination with the requirement of immunosuppression results in this approach being available to only about 10% of individuals living with type 1 diabetes (T1D). Therefore, approaches that increase islet survival and reduce the requirements of immunosuppression will make islet transplantation available to a broader T1D population. This research will use two therapeutic delivery systems, composed of biomaterials (polylactic-co-glycolic acid; PLGA), to enhance islet graft survival and function when transplanted into the subcutaneous site (under the skin). First, a bio-active scaffold will provide structural support to the transplanted islets and create a subcutaneous environment that facilitates their optimal functioning. Additionally, the delivery systems will release therapeutic substances in a controlled manner, targeting key factors that influence the success of islet transplantation. In this manner, we seek to enhance the survival and function of islets and improve overall transplantation outcomes.
Alejandro Schcolnik-Cabrera, MD/PhD
Postdoctoral Fellow
Supervisor: Sue Tsai, University of Alberta
Early life determinants of T1D progression – viewed from the lens of the gut-pancreas axis
Type 1 diabetes (T1D) is an autoimmune condition where T cells attack the pancreatic insulin-producing cells. This disease is associated with metabolic alterations related to gut microbiota, which is modulated by early exposure to maternal factors such as breast milk. Interestingly, breast milk is an important source of immunoglobulin A, which maintains microbiota homeostasis. In this project, we will identify the roles of IgA and other metabolites found in breast milk in the gut immune and metabolic pathways, trying to dissect how they regulate microbiota and T1D. We expect to predict key pathways related to slow vs fast progressing T1D individuals, with the use of endoscopy colon biopsies, RNA sequencing and machine learning algorithms.
Youngmin Song
PhD Student
Supervisor: Cristina Nostro, University of Toronto
Enhancing stem cell-derived islet replacement therapies for treating type 1 diabetes by the co-transplantation of islet cells and macrophages
Islet-like cells can be generated in vitro from human pluripotent stem cells and can be a potential alternative for cadaver pancreases in transplantation therapies for T1D patients. Clinical trials using stem cell-derived pancreatic cells have been initiated and provide proof of principle that this approach is viable. However, improving tissue engraftment and preventing rejection to ensure long-term graft functionality remain issues for both deceased donor- and stem cell-derived islets. This project will explore ways that stem cell-derived macrophages, a type of innate immune cell with many diverse functions, can be used to improve stem cell-derived islet cell transplantation.
Jia Zhao
Postdoctoral Fellow
Supervisor: Tim Kieffer, University of British Columbia
Modelling human pancreas diseases with a novel stem cell derived islet spheroid system
With breakthroughs in uncovering the process by which islet cells develop naturally in the body, it is now possible to reproduce many steps of this process in the laboratory with cultured stem cells, culminating in insulin producing islets. This research will further enhance current islet cell manufacturing approaches by incorporating a defined morphogenesis that occurs during normal islet development. In this manner, we can establish an experimental and biomimetic human islet model from stem cells in a dish. This new model system will then be used as a platform to facilitate studies to explain pancreas disease mechanisms and test new therapies to promote islet (re)generation.
October 23, 2023 (Ottawa/Toronto) – JDRF Canada and the Stem Cell Network are pleased to announce Dr. Sing-Young Chen as the 2023 J. Andrew McKee Fellow in Type 1 Diabetes (T1D). The announcement was made today in Toronto at the Till & McCulloch Meetings, Canada’s premier stem cell and regenerative medicine conference.
The J. Andrew McKee Fellowship in Type 1 Diabetes, aims to help accelerate Canadian research, develop talent and enhance Canada’s global leadership in T1D research. The Fellowship Program is named in honour and memory of John Andrew McKee, who was Past President and CEO at JDRF and a long-standing member and Chair of SCN’s Board of Directors. Andrew played a significant role in developing the future of both organizations and believed deeply in the important role of science in making Canada a better place for all.
Dr. Chen’s work focuses on understanding sex differences in beta-cell resilience to stresses associated with T1D. In type 1 diabetes, the insulin-secreting beta-cells are subject to many stresses – for example, they are attacked by the immune system and there is a high demand for insulin. Pancreatic islets from females are more resilient to these stresses than islets from males and can survive to keep making insulin. Dr. Chen’s research seeks to understand and leverage these sex differences with a view to develop cell therapies that will thrive in a T1D environment.
Dr. Chen completed her undergraduate degree at the University of Sydney, studying biochemistry and physiology. During her undergraduate studies, she was fortunate to take part in a summer research program at Vanderbilt University, which is when she first became interested in islet biology. Then, she completed her PhD at the University of New South Wales, where she studied obesity and obesity-related diseases, with a focus on physiology and drug development.
Dr. Chen is now at UBC for her postdoctoral training where she is investigating sex differences in islet responses to stress, with the hope of developing novel treatments for type 1 diabetes.
Quick Facts:
T1D is an autoimmune disease that affects the daily lives of approximately 300,000 Canadians. It occurs when the body’s immune system attacks and destroys the cells in the pancreas that make insulin.
Stem cell therapy holds immense promise for the treatment of people with diabetes, by offering the potential for the body to one day start producing its own insulin again.
The J. Andrew McKee Fellowship in Type 1 Diabetes, supported by JDRF and SCN will award one yearlong fellowship per year through 2026, with a value of $60,000 CAD per year, for a fellow working at the JDRF Centre of Excellence at UBC. Applications for the 2024 Fellowship are set to open on November 1, 2023.
The JDRF Centre of Excellence at UBC was established in December 2021 and is exclusively focused on research to cure T1D.
Quotes:
“On behalf of all of us at the Stem Cell Network, I’d like to extend a very big congratulations to Dr. Chen. Dr. Chen’s work in advancing our understanding of islet cell biology represents a crucial step in our relentless pursuit of a cure for type 1 diabetes, a disease that impacts the lives of over 300,000 Canadians. We are honoured to continue the legacy of the late Andrew McKee through our ongoing partnership with JDRF Canada that supports research fellows dedicated to advancing treatments and therapies for type 1 diabetes. Andrew had an unwavering belief that innovative advances would be forged by the next generation of brilliant minds. We are proud to be part of this journey as we strive to turn Andrew’s vision into a reality.” – Cate Murray, President and CEO, Stem Cell Network
“Andrew McKee was an impactful leader for JDRF and was a significant driving force behind the kind of T1D research that this Fellowship supports. We are so pleased to continue our partnership with SCN to provide new opportunities for trainees at the JDRF Centre of Excellence at UBC, which alongside its exciting research goals has an outstanding multidisciplinary training program. Dr. Chen’s work will help us better understand the mechanisms behind beta cells which will help move us ever closer to cures for type 1 diabetes.” – Jessica Diniz, President and Co-CEO, JDRF Canada
“We all go into science with high hopes of making a real impact to change lives for the better. This fellowship supports me to do just that, not only with funding, but also by connecting incredible networks of scientists, clinicians, and stakeholders to share knowledge and ideas that drive research forward in the right directions. Science is often described as a team sport, but it’s more than that – it’s a conglomeration of many diverse, colourful, passionate teams all working together to pursue a common goal, and I am thrilled to be a part of it!” – Dr. Sing-Young Chen, new J. Andrew McKee Fellow in Type 1 Diabetes
About the Stem Cell Network: The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, SCN’s goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has grown from a few dozen labs to more than 270 world-class research groups, supporting over 250 research projects and 30 clinical trials. Since its inception, over 25 biotech companies have been catalyzed or enhanced and more than 6,400 highly qualified personnel have been trained. In 2021, the Government of Canada demonstrated its continuing trust and support in SCN with an investment of $45 million for the 2022–2025 period.
About JDRF: JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our goal is to raise funds to support the most advanced international T1D research and progressively remove the impact of this disease from people’s lives – until we achieve a world without it. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. For more information, please visit jdrf.ca.
Canada-wide, October 1, 2023 – One of Canada’s longest running and top fundraising events will be taking place in Montréal, QC, Toronto, ON and Calgary, AB on October 5, 12 and 19, respectively. The Sun Life Ride to Defeat Diabetes for JDRF is a high-energy event that sees hundreds of corporate executives and teams shed their business wear for workout clothes to pedal for a cure for type 1 diabetes (T1D). Participants from corporate Canada will take part by spinning on hundreds of stationary bikes set up in three major cities. Additional events are being coordinated in corporate headquarters, gyms, and spin studios across the country as supporters Ride in support of JDRF throughout the month of October, towards our ultimate finish line: a world without T1D.
T1D is an autoimmune condition impacting almost 300,000 Canadians. Since the Ride launched in 1988, corporate Canada has raised millions of dollars to accelerate the pace of T1D research. Due to advances in research over the past five decades, approximately 25 years have been added to the lifespan of a person living with T1D and receiving the latest care.
“The Ride is an exciting team building event that lets people take a break from their offices, Zoom and Teams meetings, to pedal for a cure alongside their colleagues in support of people living with type 1 diabetes. People are eager to come together, so we are thrilled to be expanding this year, with events in Montréal and Toronto, and now Calgary, says Dave Prowten, CEO of JDRF Canada. “We are grateful that Sun Life and corporate Canada will move their work aside and move us closer to a cure for type 1 diabetes by helping us reach our $2.6 million fundraising goal.”
Sun Life has been a proud supporter of the Ride since 2017, and in 2019 they became the national title sponsor.
“Diabetes is a growing disease that affects millions across the world,” said Dave Jones, President, Sun Life Health. “With more than 300,000 Canadians currently living with type 1 diabetes, we’re committed to helping them live healthier lives. Thank you to JDRF for their continued effort in searching for a cure and positively impacting the lives of those affected by diabetes.”
-30-
About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit breakthrought1d.ca.
Sun Life in the Community
Sun Life is sustainability-driven, focusing on areas where it can have the greatest impact. By actively supporting the communities in which Sun Life lives and works, the organization can help build a positive environment for Clients, employees, advisors, and shareholders. Physical health and mental health are at the centre of our philanthropic support, with a focus on supporting programs and organizations that strive to empower people in Canada to live their healthiest lives no matter where they are in their journey. Sun Life employees and advisors take great pride in volunteering and giving back to make life brighter for individuals and families across Canada.
September 12, 2023 – Canada-wide – Mental health matters. Especially for those living with diabetes, a chronic condition affecting more than 4 million Canadians.
Diabetes can be a very challenging condition to live with, often requiring constant planning and vigilance, but a strong support network and the right care help to reduce the burden. However, it isn’t always easy to find the necessary support, especially when it comes to mental health.
To better help address some of the many gaps in mental health support for people with diabetes, in 2021, JDRF Canada launched a Mental Health Strategy to fund research, train mental health providers, and engage and educate healthcare providers and the type 1 diabetes community on mental health. Collaborations and partnerships with organizations like Diabetes Canada and others working in the areas of diabetes and mental health has been crucial to see the strategy develop and be realized.
The Mental Health + Diabetes Training Program, designed and implemented by JDRF Canada in collaboration with Diabetes Canada, aims to help to fill a gap in Canadian health systems. This bilingual program, launched in late 2022, provides knowledge and tools to help registered Canadian mental health providers deliver the best support to their clients with type 1 or type 2 diabetes, and expand the capacity of health systems to meet this currently underserved need.
As a result, JDRF Canada, in collaboration with Diabetes Canada is able to launch the Mental Health + Diabetes Directory. The Directory is intended to act as a connection tool, to provide people living with or affected by diabetes with access to information about registered mental health providers who have engaged in additional training to provide mental health support specific to addressing the realities of living with diabetes. Every mental health provider included in the Directory has successfully completed the Mental Health + Diabetes Training Program. The Directory will continue to expand as more mental health providers are trained.
Both the Training Program and Directory will help to close gaps in both the delivery of and access to mental health supports for those living with diabetes across Canada.
Dr. Sarah Linklater, Chief Scientific Officer – JDRF Canada “Through the Mental Health + Diabetes Training Program and now the launch of the Directory, JDRF Canada aims to increase the capacity of Canadian mental health providers to support people with diabetes and, in turn, improve their quality of life and health outcomes. Working together with Diabetes Canada will allow us to expand the reach of these initiatives and we continue to be so grateful for their support and collaboration.”
Laura Syron, CEO & President – Diabetes Canada “As someone who lives with diabetes, I know first-hand the strain this chronic condition can place on your mental and emotional health. Through innovative partnerships like this one with JDRF, Diabetes Canada is proud to play a role in building better mental health supports and care for people living with diabetes in Canada. This directory will empower health-care providers to address the holistic needs of their patients and provide them with the resources and tools to live well with their condition.”
Monica Murray, M.Ed. (OACCPP), RP “The upcoming launch of The Mental Health + Diabetes Directory is an exciting initiative from JDRF Canada and Diabetes Canada. This directory will feature professionals who understand the complexities associated with this chronic disease since they have all completed extensive training on the diabetes-specific challenges experienced by clients with type 1 or type 2 diabetes. The Mental Health + Diabetes Directory will be an excellent resource for clients with diabetes and for their family members as well.”
Henri Ng-Wan, CRHA When I received my diagnosis, I remember having a tough time accepting my new reality. After a few months, I got the courage to ask my endocrinologist for a referral and even though she wanted to help me, she was not able to give me any reference as she was also struggling to find mental health specialists for other patients. The same thing happened when I reached out to a Quebec-based association whose mission is to support people living with diabetes. The directory responds to the needs of our community and was a missing tool for our healthcare professionals.
About JDRF Canada JDRF Canada is the leading charitable organization funding type 1 diabetes (T1D) research in Canada. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our shared vision of a world without T1D. For more information, please visit breakthrought1d.ca
About Diabetes Canada
A world free of the effects of diabetes is our vision. That’s why we’re working together to improve the quality of life of people living with diabetes. We’re sharing knowledge and creating connections for individuals and the health-care professionals who care for them; advocating through public policy; and funding research to improve treatments and find a cure to end diabetes.
Media Contacts Ruth Kapelus National Content and Media Relations Manager, JDRF Canada T. 647.789.2322 E. rkapelus@jdrf.ca 235 Yorkland Blvd., Suite 600 Toronto, ON M2J 4Y8 breakthrought1d.ca
Leah Siversky Senior Manager, Communications & Public Relations T: 416.408.7041 E: leah.siversky@diabetes.ca 1300-522 University Ave., Toronto, ON M5G 2R5 diabetes.ca
August 2nd, 2023 – British Columbia – The Government of British Columbia announced yesterday that the FreeStyle Libre, a flash glucose monitoring (Flash GM) device, will be covered by BC PharmaCare as a limited-coverage benefit for people living with type 1 diabetes (T1D) beginning August 1st 2023.
Prior to this announcement, public coverage in British Columbia was limited to only the Dexcom G6 continuous glucose monitor (CGM).
JDRF is a strong proponent of equitable access to a variety of T1D technologies, including pumps, CGMs and Flash GMs. People living with T1D deserve to be able to choose which device is most suitable to both meet their health needs and best manage their disease. Yesterday’s announcement improves patient choice by adding another device that is publicly covered for British Columbians living with T1D.
In British Columbia, it is estimated that 34,000 people live with T1D. For these individuals, managing their condition daily involves monitoring their blood glucose levels and administering insulin through injections or insulin pumps. Each insulin dosage needs to be meticulously tailored, taking into account their carbohydrate intake and physical activity. Despite this careful management, people with T1D still remain vulnerable to a variety of serious complications such as kidney disease, vision impairment, amputation, and even death.
Use of devices like Flash GMs have been shown to reduce hospitalizations and the risk of longer-term complications for its users. They also help to ease some of the anxiety from living with T1D by allowing individuals to better plan activities around the disease including exercise, meals, and rest. These devices are not simply a luxury – they are lifesaving technologies.
Through its #AccessForAll advocacy campaign, JDRF Canada has been working to help make a variety of T1D technologies affordable and accessible for all Canadians living with the disease. In doing so, this campaign works to improve lives by helping to alleviate the financial, physical, and mental health burdens associated with T1D.
“JDRF Canada celebrates the announcement from British Columbia to offer greater patient choice to those living with type 1 diabetes. By introducing a flash glucose monitor into its coverage, the Government of British Columbia recognizes the value of proper diabetes management and how diabetes technology can benefit not just the patient, but also the healthcare systems that support them. We applaud this decision to enable safer and healthier lives for everyone living with type 1 diabetes” says Dave Prowten, CEO of JDRF Canada.
In 2022, JDRF commissioned a cost effectiveness study to support advocacy efforts towards expanded provincial public coverage. The study examined population level impact on diabetes-related complications, mortality, and cost effectiveness of the three glucose monitoring techniques used by adults with T1D in Canada. While provincial coverage of these devices represents a high short-term investment, it is overshadowed by significant long-term cost savings due to reduced complications, hospitalizations, and additional medical interventions.
Since 2019, JDRF’s Access for All campaign has engaged passionate advocates from T1D communities across the country with proven results. With support from JDRF, they are making their voices heard and has driven change in several provinces and territories to improve access.
JDRF Canada is the leading charitable organization funding type 1 diabetes (T1D) research in Canada. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. Since our founding in 1974, JDRF has invested more than $80 million CDN in research funding. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our shared vision of a world without T1D. For more information, please visit breakthrought1d.ca.
For more information:
Monica Kocsmaros Chief External Relations Officer T. 647.354.5598 E. mkocsmaros@jdrf.ca 235 Yorkland Blvd., Suite 600, Toronto, ON M2J 4Y8 breakthrought1d.ca
Helena Gottschling, Chair of the JDRF Canada Board of Directors is pleased to announce the appointment of Jessica Diniz as their next President & CEO, effective January 1, 2024.
“We congratulate Jessica on her appointment and will benefit from her depth of experience in the non-profit sector, passion for the cause and fundraising experience” says Helena Gottschling. “The board is confident that Jessica is the right leader at the right time to help us build on successes to-date and drive our mission forward.”
Dave Prowten, who has led the organization for over 10 years as President & CEO will be retiring at the end of 2023 and he is looking forward to spending more time with his family. His leadership has been instrumental in increasing JDRF’s mission impact, extending research partnerships and passionately advocating for all Canadians living with T1D.
“On behalf of the Board, I would like to extend our deepest gratitude to Dave for his exceptional leadership and dedication to JDRF as President & CEO”, says Helena Gottschling.
Dave’s legacy includes establishing critical partnerships with government, partners and other diabetes organizations to further our mission, significantly improving the reimbursement landscape for all Canadians living with type 1 diabetes and representing the T1D community with conviction at every opportunity. It is now an exciting time to pass the torch over to his successor to build on the momentum JDRF has been experiencing and create lasting impact for the type 1 diabetes community.
Jessica Diniz is a seasoned senior executive with over 20 years’ experience in strategic fundraising and leading high-performance teams. Jessica joined JDRF in 2015, where she has led the strategy to pivot JDRF from being events-based, to a highly impactful, effective fundraising organization. Most recently, Ms. Diniz launched JDRF’s largest major gift campaign to-date, the JDRF’s $100M Campaign to Accelerate in 2020, shifting the organization to a donor-centred fundraising model. Prior to her time at JDRF, Jessica held senior roles at both Sunnybrook Foundation and Cystic Fibrosis Foundation.
“I am thrilled to take on this new challenge. In the past few years, JDRF has undergone transformational change in driving more dollars to its mission. I am excited to build on this momentum and continue to ask – how do we help Canadians living with T1D, in the most impactful way. It will be an honour to work alongside the incredibly talented JDRF staff, and deeply passionate and skilled volunteers towards this goal.” – Jessica Diniz
“It has been a privilege to lead JDRF and serve the passionate type 1 diabetes community. This is an incredibly exciting time in type 1 diabetes research and Jessica brings tremendous experience and extraordinary commitment, and I am confident she will lead JDRF to new heights and accelerate our mission.” – Dave Prowten
For more information: Monica Kocsmaros Chief External Relations Officer E: mkocsmaros@jdrf.ca T: 647 354 5598
